RE: Croda bid at 20p?18 Feb 2026 12:20
I asked Goggle AI if croda buying skin therapeutic would be good for Croda… this was its answer ⬇️⬇️⬇️
Based on the strong existing partnership, an acquisition of SkinBioTherapeutics (SBTX) by Croda International would likely be a highly strategic and beneficial move for Croda, allowing it to fully control a key, high-growth, and sustainable technology in the burgeoning skin microbiome sector.
Here is an analysis of why this acquisition would likely be good for Croda:
1. Control of High-Growth Proprietary Technology
SkinBiotix® Exclusivity: Croda (via its Sederma division) already has an exclusive license for SkinBioTherapeutics' SkinBiotix® technology in the cosmetic sector, which it has rebranded as Zenakine™.
Next-Generation Active: Zenakine™ is a, "neuroactive" ingredient that acts on the skin-brain axis to manage stress, improve skin health, and enhance sleep quality. It is viewed as a potential successor to Croda's blockbuster, Matrixyl, according to market speculation.
Complete Control: Buying the company outright allows Croda to control the entire IP pipeline, including future applications in infection control, wound healing, and, "AxisBiotix" (gut-skin axis) food supplements, rather than just licensing one portion.
www.skinbiotherapeutics.com
www.skinbiotherapeutics.com
+6
2. Alignment with Sustainability and "Clean Beauty"
Natural Alternative: As consumers and regulators demand safer, non-toxic, and natural products, the probiotic-derived lysates from SkinBioTherapeutics offer a sustainable alternative to synthetic peptides.
PFAS-Free Focus: Croda is aggressively transitioning to become PFAS-free by 2026. SkinBiotix® fits perfectly into this strategy as a natural alternative that does not rely on synthetic manufacturing.
3. Synergies and Market Access
Leveraging Sederma's Scale: SkinBioTherapeutics has stated its desire to partner with established players to scale up. Croda has the global distribution network (>12,000 customers) and manufacturing capacity to turn SkinBio's technology into a high-volume product.
"Win-Win" Integration: SkinBioTherapeutics has recently acquired its own manufacturing capabilities (Dermatonics, Bio-Tech Solutions), which means a potential acquisition by Croda would bring in-house,, "GMP standards and ISO certified" manufacturing facilities, further enhancing efficiency